Beta Bionics, Inc. (BBNX) Balance Sheet

NASDAQ: BBNXAssets, liabilities, debt and equity over 4 years.

BBNX balance sheet, 2025

December 31, 2025 · U.S. dollars

$328.7M assets = $41.1M liabilities + $287.6M equity

What it owns$328.7MCash & ST investments: $219.1M (66.7%)Cash & ST investments$219.1M · 67%Receivables: $19.9M (6.1%)Receivables $19.9MInventory: $21.7M (6.6%)Inventory $21.7MOther current: $7.2M (2.2%)PP&E: $15.2M (4.6%)LT investments: $45.4M (13.8%)LT investments$45.4M · 14%Other non-current: $180,000 (0.1%)=How it is financed$328.7MCurrent liabilities: $30.9M (9.4%)Current liabilities $30.9MOther LT liabilities: $10.2M (3.1%)Shareholders’ equity: $287.6M (87.5%)Shareholders’ equity$287.6M · 87%

Both columns are drawn to the same scale: what BBNX owns equals what it owes plus shareholders’ equity. Hover a block for its value.

BBNX financial health

Current ratio8.66
Comfortable · current assets cover current liabilities 8.66×
Debt / equity0.03
Low leverage · $0.03 of debt for each $1 of equity
Equity / assets87.5%
Equity-funded · of assets funded by shareholders
Cash / debt3,000.5%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

BBNX balance sheet trends, 2022–2025

Beta Bionics, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$35.5M2022$328.7M2025+109.9%/yr
Total liabilities$205.6M2022$41.1M2025−41.5%/yr
Shareholders’ equity−$170.0M2022$287.6M2025—
Cash & short-term investments$27.7M2022$219.1M2025+99.3%/yr
Total debt$4.1M2022$7.3M2025+20.9%/yr
Net cash (debt)$23.5M2022$211.8M2025+$188.3M
Working capital$19.6M2022$237.0M2025+$217.4M
Book value per share−$3.972022$7.102025—
Current ratio3.2120228.662025+5.46
Debt / equity0.0720230.032025−0.05
Shares outstanding42.9M202240.5M2025−1.8%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

BBNX assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

BBNX liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

BBNX debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

BBNX balance sheet

Beta Bionics, Inc. annual balance sheet
2025202420232022
Assets
Cash & short-term investments$219.1M$103.6M$96.7M$27.7M
Cash & equivalents$31.6M$30.4M$26.6M$27.7M
Short-term investments$187.5M$73.1M$70.2M$0
Receivables$19.9M$12.0M$4.4M$0
Inventory$21.7M$13.3M$1.2M$0
Other current assets$7.2M$4.0M$1.2M$792,000
Total current assets$267.9M$132.9M$103.6M$28.5M
Property, plant & equipment (net)$15.2M$11.4M$6.2M$6.9M
Goodwill & intangible assets$0$0$0$0
Long-term investments$45.4M$0$0$0
Other non-current assets$180,000$5.3M$221,000$193,000
Total assets$328.7M$149.6M$110.0M$35.5M
Liabilities
Accounts payable$5.0M$2.9M$1.2M$430,000
Short-term debt$1.9M$1.5M$1.2M$976,000
Deferred revenue$1.6M$939,000$87,000—
Total current liabilities$30.9M$21.1M$10.6M$8.9M
Long-term debt$0$0$0$0
Lease obligations$7.3M$7.3M$4.2M$4.1M
Other long-term liabilities$10.2M$52.5M$40.8M$196.7M
Total liabilities$41.1M$73.6M$51.4M$205.6M
Shareholders' equity
Common stock & paid-in capital$4,000$1,000$1,000$1,000
Retained earnings (deficit)−$369.9M−$296.7M−$229.7M−$185.6M
Accumulated other comprehensive income$403,000$65,000$137,000—
Total shareholders' equity$287.6M$76.0M$58.6M−$170.0M
Key figures
Total debt$7.3M$7.3M$4.2M$4.1M
Net cash (debt)$211.8M$96.3M$92.5M$23.5M
Working capital$237.0M$111.8M$93.0M$19.6M
Tangible book value$287.6M$76.0M$58.6M−$170.0M
Book value per share$7.10$1.77$1.37−$3.97
Shares outstanding40.5M42.9M42.9M42.9M
Current ratio8.666.299.773.21
Quick ratio7.735.469.543.12
Debt / equity0.030.100.07—
Equity / assets87.5%50.8%53.3%−478.6%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 24, 2026); data from EODHD.

BBNX financial position

At the end of fiscal 2025 (December 31, 2025), Beta Bionics had total assets of $328.7 million (up 119.7% from a year earlier), total liabilities of $41.1 million and shareholders' equity of $287.6 million. It held $219.1 million in cash and short-term investments against $7.3 million of debt, a net cash position of $211.8 million. Its current ratio was 8.66. In the latest quarter (ended June 30, 2026) total assets were $292.4 million and equity $256.4 million.

Related: BBNX income statement, BBNX cash flow statement, BBNX key metrics. See the BBNX stock overview for the latest quote and news.

BBNX balance sheet FAQ

What are Beta Bionics's total assets?

Beta Bionics reported total assets of $328.7 million at the end of fiscal 2025 (December 31, 2025), compared with $149.6 million a year earlier.

How much debt does Beta Bionics have?

Beta Bionics had $7.3 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.03.

How much cash does Beta Bionics have?

Beta Bionics held $219.1 million in cash and short-term investments at the end of fiscal 2025; with $7.3 million of debt that is net cash of $211.8 million.

What is Beta Bionics's book value?

Beta Bionics's shareholders' equity (book value) was $287.6 million at the end of fiscal 2025, or $7.10 per share.

What is Beta Bionics's current ratio?

Beta Bionics had current assets of $267.9 million and current liabilities of $30.9 million, a current ratio of 8.66 (it can cover its short-term obligations).

Medical Devices: balance sheet